Skip to main content
Publications
Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Omland LH, Holm-Hansen C, Lebech AM, Dessau RB, Bodilsen J, Andersen NS, Roed C, Christiansen CB, Ellermann-Eriksen S, Midgley S, Nielsen L, Benfield T, Hansen AE, Anderson CO, Rothman KJ, Sorensen HT, Fischer TK, Obel N. Long-term survival, health, social functioning, and education in patients with an enterovirus central nervous system infection, Denmark, 1997-2016. J Infect Dis. 2020 Jul 23;222(4):619-27. doi: 10.1093/infdis/jiaa151
Young-Xu Y, Van Aalst R, Mahmud SM, Rothman KJ, Thornton Snider J, Westreich D, Mor V, Gravenstein S, Lee JKH, Thommes EW, Decker MD, Chit A. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration Patients. J Infect Dis. 2018 May;217(11):1718-27. doi: 10.1093/infdis/jiy088